Are you a Patient?

Canxiol is committed to the ongoing safety surveillance of our prescription medicines. If you or someone in your care has experienced a suspected adverse reaction, please choose the pathway below to access the appropriate reporting documents and procedures.

Patients

Report an adverse effect

If you are taking Canxiol and experiencing unexpected symptoms or side effects, you can report them directly using the official consumer reporting forms provided through the Pharmacovigilance Programme of India.

Patient ADR Reporting Forms

10 Languages

Select a language to download the official consumer adverse drug reaction reporting form.

Submit completed report

Send the completed ADR form directly to the Leiutis Pharmacovigilance safety team.

Secure Transmission: Submissions are encrypted via HTTPS and handled under strict confidentiality in compliance with medical data privacy regulations.

Upload completed ADR form (PDF, DOCX, Scan)

Recipient: [ write@leiutis.com ]

Regulatory Authority Distinction

Pharmacovigilance Programme of India (PvPI)

The Pharmacovigilance Programme of India (PvPI), initiated by the Indian Pharmacopoeia Commission (IPC) under the Ministry of Health & Family Welfare, monitors adverse drug reactions to ensure patient safety across India. Leiutis operates in full coordination with IPC/PvPI reporting directives.

IPC ADR reporting forms
Pharmacovigilance & Safety Monitoring

Reporting a adverse effect

Healthcare professionals and patients are encouraged to report any suspected adverse reactions.

Leiutis Medical & Pharmacovigilance Center

Please write to us for any adverse effects

Direct Phone:
+91 40 23077365

India’s Pharmacovigilance Programme (PvPI)

Adverse events can also be reported to the national pharmacovigilance centre under the Indian Pharmacopoeia Commission (IPC):

National Toll-Free:
1800-180-3024